You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
McKinsey
Merck
Mallinckrodt
Colorcon

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

LOVENOX Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Lovenox patents expire, and when can generic versions of Lovenox launch?

Lovenox is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in LOVENOX is enoxaparin sodium. There are thirteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the enoxaparin sodium profile page.

US ANDA Litigation and Generic Entry Outlook for Lovenox

A generic version of LOVENOX was approved as enoxaparin sodium by SANDOZ INC on November 28th, 2011.

  Start Trial

Drug patent expirations by year for LOVENOX
Drug Prices for LOVENOX

See drug prices for LOVENOX

Drug Sales Revenue Trends for LOVENOX

See drug sales revenues for LOVENOX

Recent Clinical Trials for LOVENOX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Weill Medical College of Cornell UniversityPhase 4
Columbia UniversityPhase 4
Northwell HealthPhase 3

See all LOVENOX clinical trials

Pharmacology for LOVENOX
Paragraph IV (Patent) Challenges for LOVENOX
Tradename Dosage Ingredient NDA Submissiondate
LOVENOX INJECTABLE;INTRAVENOUS, SUBCUTANEOUS enoxaparin sodium 020164 2006-12-07
LOVENOX (PRESERVATIVE FREE) INJECTABLE;SUBCUTANEOUS enoxaparin sodium 020164 2006-12-07

US Patents and Regulatory Information for LOVENOX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003 AB RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-005 Mar 27, 1998 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-003 Mar 27, 1998 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-007 Jun 2, 2000 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-001 Mar 29, 1993 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-002 Jan 30, 1998 AP RX Yes No   Start Trial   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX (PRESERVATIVE FREE) enoxaparin sodium INJECTABLE;SUBCUTANEOUS 020164-006 Jun 2, 2000 DISCN Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for LOVENOX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003   Start Trial   Start Trial
Sanofi Aventis Us LOVENOX enoxaparin sodium INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 020164-009 Jan 23, 2003   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Colorcon
Baxter
Dow
Moodys
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.